uniQure's AMT-260 Gene Therapy Shows 79-100% Seizure Reduction in Some Epilepsy Patients
QURE has more than doubled off its 52-week low of $8.73 on elevated volume (2.3× avg).
Summary
uniQure announced preliminary Phase I/IIa data for its gene therapy candidate AMT-260 in refractory mesial temporal lobe epilepsy, showing positive safety and early efficacy signals. Three of six patients in the low-dose cohort achieved significant seizure reductions ranging from 79% to 100%. This early data for a new pipeline asset adds to the company's recent positive developments, including the planned BLA submission for AMT-130 in Huntington's disease. The positive safety profile and observed responses support continued evaluation of AMT-260, with updated results from a higher dose cohort expected in the first half of 2027.
At the time of this announcement, QURE was trading at $46.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $8.73 to $71.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.